# Empagliflozin on Residual Kidney Function in Incident Peritoneal Dialysis Patients

> **NCT06483074** · PHASE2 · RECRUITING · sponsor: **Chinese University of Hong Kong** · enrollment: 48 (estimated)

## Conditions studied

- End Stage Renal Disease on Dialysis
- Peritoneal Dialysis Complication
- Sodium-glucose Cotransporter-2 Inhibitor
- Residual Kidney Function

## Interventions

- **DRUG:** Empagliflozin 10 MG

## Key facts

- **NCT ID:** NCT06483074
- **Lead sponsor:** Chinese University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-29
- **Primary completion:** 2026-07-31
- **Final completion:** 2026-10-31
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2025-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06483074

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06483074, "Empagliflozin on Residual Kidney Function in Incident Peritoneal Dialysis Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06483074. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*